This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Kragt, J J Articles by Polman, C H Search for Related Content PubMed PubMed Citation Articles by Kragt, J J Articles by Polman, C H Social Bookmarking                   What's this?

Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis

Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, JJ.Kragt{at}vumc.nl

F AH van der Linden

Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Department of Medical Psychology, VU University Medical Centre, Amsterdam, The Netherlands

J M Nielsen

Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands

B MJ Uitdehaag

Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands, Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands

C H Polman

Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands

Introduction: Quantitative tests of motor function, like the Timed 25-foot Walk (T25FW) and 9-hole Peg Test (9HPT), are increasingly being applied as outcome measures in multiple sclerosis (MS) clinical trials. The quantitative nature of the data has a favorable impact on responsiveness, but the clinical impact of the changes is uncertain. The goal of this study was to assess whether a change on T25FW and 9HPT does indeed have a clinical meaning. This was accomplished by comparing 20% changes on these quantitative measurements to concomitant changes on the Guy’s Neurological Disability Scale (GNDS), a scale which measures patient-perceived daily life disability.

Methods: From a longitudinal database, we selected patients with at least two measurements of T25FW, 9HPT and GNDS with a minimal time interval of 350 days. In those patients who experienced at least a 20% change on T25FW or 9HPT, GNDS score changes were examined more closely.

Results: Of 527 patients, 143 experienced a >20% worsening on their T25FW and 71 on their 9HPT, respectively. Patients with a 20% increase in T25FW or 9HPT had more GNDS worsening than patients without such an increase. GNDS worsening associated with an increase in T25FW was mainly due to an increase in perceived disability related to lower extremity function and fatigue; GNDS worsening associated with an increase in 9HPT was more diffuse with respect to domains involved.

Conclusion: Worsening on T25FW or 9HPT has a clinical impact on disability, as perceived by MS patients during daily life functioning.

Key Words: clinical scale • GNDS • 9HPT • MSFC • multiple sclerosis • T25FW

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Schmitz-Hubsch, P. Giunti, D. A. Stephenson, C. Globas, L. Baliko, F. Sacca, C. Mariotti, M. Rakowicz, S. Szymanski, J. Infante, et al. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia Neurology, August 12, 2008; 71(7): 486 - 492. [Abstract] [Full Text] [PDF]

				L. Contelloe and M. Hutchinson Is a 20% change in MSFC components clinically meaningful? Multiple Sclerosis, September 1, 2007; 13(8): 1076 - 1076. [PDF]